Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS
2020 · Journal of Hepatology · 183 citations
https://doi.org/10.1016/j.jhep.2020.04.024
A
Arnulf Ferlitsch
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
299
Papers
7.2K
Citations
48
h-index
100
i10-index
Arnulf Ferlitsch is an academic researcher from Hospital of the Brothers of St. John of God. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation & Hepatitis C virus research. The author has an h-index of 48, co-authored 255 publications.
ORCID: 0000-0002-5281-0780Papers by this author
worksSedation in Screening Colonoscopy: Impact on Quality Indicators And Complications
2012 · The American Journal of Gastroenterology · 106 citations
https://doi.org/10.1038/ajg.2012.347
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study
2011 · Alimentary Pharmacology & Therapeutics · 96 citations
https://doi.org/10.1111/j.1365-2036.2011.04896.x
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
2023 · Wiener klinische Wochenschrift · 53 citations
https://doi.org/10.1007/s00508-023-02229-w
Response to Shaikh et al.
2013 · The American Journal of Gastroenterology · 0 citations
https://doi.org/10.1038/ajg.2013.35
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat